Phillyrin is an effective inhibitor of quorum sensing with potential as an anti-&lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; infection therapy

Zhou, Shuxin; Zhang, An; Chu, Weihua

doi:10.1292/jvms.18-0523

Cited by 15 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to severe cases, the Chinses herbal injections could obviously alleviate clinical symptoms and correct complications. In particular, Xuebijing injection was widely used for treating patients with critical diseases including sepsis, severe pneumonia, severe acute pancreatitis, infection-induced systemic inflammatory response syndrome, chronic obstructive pulmonary disease (COPD), ARDS, multiple organ dysfunction syndrome (MODS) and so on [104,105]. Moreover, our study highlighted that its clinical beneficial effects in severe cases was closely associated with the inhibition of cytokine storm, improve virus infection and lung injury, superior binding activities with 3CLpro and ACE2.…”

Section: Discussionmentioning

confidence: 99%

The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence

Zhang

et al. 2020

Pharmacological Research

View full text Add to dashboard Cite

The outbreak of emerging infectious pneumonia caused by 2019 Novel Coronavirus (2019-nCoV) has posed an enormous threat to public health, and traditional Chinese medicine (TCM) have made vast contribution to the prevention, treatment and rehabilitation of coronavirus disease 19 (COVID-19) among Chinese population. As an indispensable part of TCM, Chinese patent medicines (CPMs) are highly valued and critically acclaimed in their campaign to contain and tackle the epidemic, they can achieve considerable effects for both suspected cases under medical observation period, and confirmed individuals with serious underlying diseases or critical conditions. Given this, based on the Guideline on Diagnosis and Treatment of Coronavirus Disease 2019 in China, the present review summarized the basic information, clinical evidence and published literatures of recommended CPMs against COVID-19. The details were thoroughly introduced involving compositions, therapeutic effects, clinical indications, medication history of CPMs and the profiles of corresponding research. With regard to infected patients with different stages and syndrome, the preferable potentials and therapeutic mechanism of CPMs were addressed through the comprehensive collection of relevant literatures and ongoing clinical trials. This study could provide an insight into clinical application and underlying mechanism of recommended CPMs against COVID-19, with the aim to share the Chinese experience in clinical practice and facilitate scientific development of TCM, especially CPMs in the fierce battle of COVID-19. million confirmed cases with COVID-19 worldwide, of these, a total of 277,965 subjects were from the United States [13,14]. According to official release on April 4, 2020 by National Health Commission of the People's Republic of China, more than 80,000 cases had been confirmed as COVID-19 with 3326 death cases [15]. Currently, the global pandemic of COVID-19 continues to accelerate and escalate, the health-care systems of different countries are beavering away to contain the virus, therefore, there is urgent need to seek for effective or adjuvant therapies with excellent safety profiles against COVID-19 [16-18]. In the theory of traditional Chinese medicine (TCM), 2019-nCoV infected pneumonia was deemed to the category of "Pestilence", and the characteristics of its pathogenesis was "dampness, toxin, stasis and closure" [19,20]. Over the past few months, TCM exhibited remarkable benefits against COVID-19 in China, and it was convinced that TCM achieved satisfactory therapeutic superiority for patients infected by 2019-nCoV with regard to preventive treatment of diseases, comprehensive therapies and rehabilitation by the

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence

Zhang

et al. 2020

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…Rhamnolipid concentrations were measured based on the standard orcinol-sulfuric acid assay (Zhou et al, 2019 ). In brief, treated cultures were grown at 37°C for 24 h before collecting 900 μL of supernatant.…”

Section: Methodsmentioning

confidence: 99%

Gregatins, a Group of Related Fungal Secondary Metabolites, Inhibit Aspects of Quorum Sensing in Gram-Negative Bacteria

2022

View full text Add to dashboard Cite

Quorum sensing (QS) is a process that regulates gene expression based on cell density. In bacteria, QS facilitates collaboration and controls a large number of pathways, including biofilm formation and virulence factor production, which lead to lower sensitivity to antibiotics and higher toxicity in the host, respectively. Inhibition of QS is a promising strategy to combat bacterial infections. In this study, we tested the potential of secondary metabolites from fungi to inhibit bacterial QS using a library derived from more than ten thousand different fungal strains. We used the reporter bacterium, Chromobacterium violaceum, and identified 39 fungal strains that produced QS inhibitor activity. These strains expressed two QS inhibitors that had been described before and eight QS inhibitors that had not been described before. Further testing for QS inhibitor activity against the opportunistic pathogen Pseudomonas aeruginosa led to the identification of gregatins as an interesting family of compounds with QS inhibitor activity. Although various gregatins inhibited QS in P. aeruginosa, these gregatins did not inhibit virulence factor production and biofilm formation. We conclude that gregatins inhibit some, but not all aspects of QS.

show abstract

“…LasR and RhlR receptors [143] Ajoene, a Sulfur-Rich Molecule from Garlic Pathogenic factors production [144] Berberine Production of biofilm, secretion of protease, pyoverdin, pyocyanin and the expressions of lasI, lasR, rhlI, rhlR genes [133] Trans-cinnamaldehyde Secretion of protease, elastase, pyocyanin and production of biofilm and the expressions of lasI, lasR, rhlI, rhlR genes [145] Salicylic acid Secretion of protease, elastase, pyocyanin and production of biofilm and the expressions of lasI, lasR, rhlI, rhlR genes [145] Phillyrin Pyocyanin, rhamnolipid, elastase, swimming and twitching motility and biofilm formation [146] Trans-anethole Swarming motility, secretion of protease, elastase, pyocyanin and the expressions of lasB gene [147] Cinnamic acid Secretion of pyocyanin, proteases, elastase and production biofilm [148] Hordenine Swarming motility, secretion of pyocyanin, elastase, rhamnolipid, production of biofilm and the expressions of lasI, lasR, rhlI, rhlR genes [149] Eugenol from clove extract Pathogenic factors and production of biofilm [150] Ocimum sanctum Secretion of pyocyanin, protease, elastase and production of biofilm [151] Musa paradisiaca Pyocyanin, protease, elastase and biofilm formation [151] Caffeine Motility phenotypes [151] Methanolic extract of Phyllanthus amarus Motility phenotypes, pyocyanin secretion [152] Zingerone Motility phenotypes, production of biofilm and pathogenic factors production [153] Combretum albiflorum Elastase secretion and production of biofilm [154] Allium sativum (garlic) extract Production of biofilm, elastase secretion [155,156] FL fraction of Psidium guajava L Virulence factors production and production of biofilm [157] Clove oil Protease, chitinase and pyocyanin secretion, swimming motility and production of biofilm [158] The methanol extract of fenugreek Protease, LasB elastase, pyocyanin and chitinase production, swarming motility and production of biofilm [159] (Continued) a wide spectrum, so it can be considered as an alternative for the treatment of P. aeruginosa infections. 105 Other attractive compounds are Engineered nanoparticles (ENPs), which are used as QSIs.…”

Section: Coumarinmentioning

confidence: 99%

<p>Quorum Quenching: A Potential Target for Antipseudomonal Therapy</p>

Hemmati¹,

Salehi²,

Ghotaslou³

et al. 2020

IDR

View full text Add to dashboard Cite

There has been excessive rate of use of antibiotics to fight Pseudomonas aeruginosa (P. aeruginosa) infections worldwide, which has consequently caused the increased resistance to multiple antibiotics in this pathogen. Due to the widespread resistance and the current poor effect of antibiotics consumed to treat P. aeruginosa infections, finding some novel alternative therapeutic methods are necessary for the treatment of infections. The P. aeruginosa biofilms can cause severe infections leading to the increased antibiotic resistance and mortality rate among the patients. In this regard, there are no approaches that can efficiently manage these infections; therefore, novel and effective antimicrobial and antibiofilm agents are needed to control and treat these bacterial infections. Quorum sensing inhibitors (QSIs) or quorum quenchings (QQs) are now considered as potential therapeutic alternatives and/or adjuvants to the current failing antibiotics, which can control the virulence traits of the pathogens, so as a result, the host immune system can quickly eliminate bacteria. Thus, the aims of this review article were presenting a brief explanation of the research reports on the natural and synthetic QSIs of P. aeruginosa, and the assessment of the current understanding on the QS mechanisms and various QQ strategies in P. aeruginosa.

show abstract

Phillyrin is an effective inhibitor of quorum sensing with potential as an anti-<i>Pseudomonas aeruginosa</i> infection therapy

Cited by 15 publications

References 34 publications

The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence

The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence

Gregatins, a Group of Related Fungal Secondary Metabolites, Inhibit Aspects of Quorum Sensing in Gram-Negative Bacteria

<p>Quorum Quenching: A Potential Target for Antipseudomonal Therapy</p>

Contact Info

Product

Resources

About